Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis.

ABSTRACT:

Objective

To examine whether rituximab induction followed by glatiramer acetate (GA) monotherapy is more effective than GA alone for the treatment of relapsing multiple sclerosis with active disease.

Methods

This was a single-center, double-blind, placebo-controlled study. Fifty-five participants were randomly assigned (1:1 ratio) to either rituximab (R-GA) or placebo (P-GA) induction, followed by GA therapy initiated in all participants. Participants were followed up to 3 years. The primary endpoint was the number of participants with no evidence of disease activity (NEDA): those without relapse, new MRI lesions, and sustained change in disability.

Results

Twenty-eight and 27 participants received rituximab and placebo induction, respectively, with one participant in

SUBMITTER: Honce JM 

PROVIDER: S-EPMC6382366 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature